Safety Study to Determine the Appropriate Dose of Antibody Against Tumor Cells to Best Target Patients With Pancreatic Cancer.

Summary

This no treatment research study is being done to find a safe and an appropriate dose of antibody (protein) against tumor cells to best target the cancer in people with pancreatic cancer. To do this, this no-treatment research study will compare two doses of an antibody called hPAM4 IgG when combined with a radioactive element, Indium-111.

Timeline

Start

2007-05

Primary completion

2008-08

Completion

2008-08

Outcome

Outcome not reported

Stopped (Business): “Loss of funding”

Drugs

Indications